



Bid Antibody (BH3 Domain Specific) Blocking peptide

Synthetic peptide Catalog # BP1307a

Specification

Bid Antibody (BH3 Domain Specific) Blocking peptide - Product Information

Primary Accession <u>P55957</u>

Bid Antibody (BH3 Domain Specific) Blocking peptide - Additional Information

Gene ID 637

Other Names

BH3-interacting domain death agonist, p22 BID, BID, BH3-interacting domain death agonist p15, p15 BID, BH3-interacting domain death agonist p13, p13 BID, BH3-interacting domain death agonist p11, p11 BID, BID

Target/Specificity

The synthetic peptide sequence used to generate the antibody AP1307a was selected from the region of human Bid BH3 Domain. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Bid Antibody (BH3 Domain Specific) Blocking peptide - Protein Information

Bid Antibody (BH3 Domain Specific) Blocking peptide - Background

Bid is a death agonist that heterodimerizes with either agonist BAX or antagonist BCL2. Bid is a member of the BCL-2 family of cell death regulators. It is a mediator of mitochondrial damage induced by caspase-8 (CASP8); CASP8 cleaves this encoded protein, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release.

Bid Antibody (BH3 Domain Specific) Blocking peptide - References

Wang, X., et al., J. Biol. Chem. 278(31):29184-29191 (2003).Cartron, P.F., et al., Mol. Cell. Biol. 23(13):4701-4712 (2003).Fischer, B., et al., Biochem. Biophys. Res. Commun. 306(2):516-522 (2003).Degli Esposti, M., et al., J. Biol. Chem. 278(18):15749-15757 (2003).Kuwana, T., et al., Cell 111(3):331-342 (2002).



Name BID

Function

The major proteolytic product p15 BID allows the release of cytochrome c (By similarity). Isoform 1, isoform 2 and isoform 4 induce ICE-like proteases and apoptosis. Isoform 3 does not induce apoptosis. Counters the protective effect of BcI-2.

Cellular Location

Cytoplasm. Mitochondrion membrane. Mitochondrion outer membrane. Note=When uncleaved, it is predominantly cytoplasmic. [BH3-interacting domain death agonist p13]: Mitochondrion membrane {ECO:0000250|UniProtKB:P70444}. Note=Associated with the mitochondrial membrane. {ECO:0000250|UniProtKB:P70444} [Isoform 3]: Cytoplasm

Tissue Location

Isoform 2 and isoform 3 are expressed in spleen, bone marrow, cerebral and cerebellar cortex. Isoform 2 is expressed in spleen, pancreas and placenta (at protein level). Isoform 3 is expressed in lung, pancreas and spleen (at protein level). Isoform 4 is expressed in lung and pancreas (at protein level)

Bid Antibody (BH3 Domain Specific) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides